retatrutide mental health Significantly Reduces Visceral Fat in Clinical Trials Is a new weight-loss drug

The study will test efpeglenatide in patients whose blood sugar is not controlled well enough with metformin and dapagliflozin, an SGLT-2 inhibitor

Therefore, although BMI is appreciated for its simplicity in categorizing subjects, it should be used with caution as a diagnostic tool and might be better used as a screening aid [10]

It is crucial to note that very low calorie diets (VLCDs) of less than 800 calories per day should only be followed under medical supervision within a structured, multicomponent weight management programme, as advised by NICE

If you are beginning GLP-1 treatment or are in the middle of your weight-loss journey we can discuss a proactive plan to support your skin as changes occur

Key takeaways Chinas GLP-1 market is booming, driven by rising diabetes and obesity prevalence, expanded indications (e.g., MASH, CKD, Alzheimers), policy support and momentum from global leaders and innovative local players